# A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).

> **NCT05895136** · PHASE2 · RECRUITING · sponsor: **European Foundation for Study of Chronic Liver Failure** · enrollment: 90 (estimated)

## Conditions studied

- Liver Cirrhosis
- Decompensated Cirrhosis of Liver
- Acute on Chronic Liver Failure (ACLF)

## Interventions

- **DRUG:** Human albumin
- **DRUG:** Enoxaparin
- **DRUG:** Standard medical treatment

## Key facts

- **NCT ID:** NCT05895136
- **Lead sponsor:** European Foundation for Study of Chronic Liver Failure
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895136, "A Novel COMBinATorial Therapy With Albumin and Enoxaparin in Patients With Decompensated Cirrhosis at High-risk of Poor Outcome (COMBAT Trial).". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05895136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*